Prognostic significance of systemic immune-inflammation index in patients with intrahepatic cholangiocarcinoma undergoing hepatic resection

Table 3 Univariate analysis in the derivation cohort

Variables	Overall survival			Recurrence-free survival
	HR	95%CI	P value	HR	95%CI	P value
Age, yr (> 60/≤ 60)	0.917	0.669-1.258	0.592	0.998	0.749-1.330	0.991
Gender (F/M)	0.747	0.546-1.023	0.069	0.791	0.594-1.052	0.107
HBsAg	1.347	0.966-1.878	0.079	1.289	0.947-1.753	0.106
Hepatolithiasis	1.775	1.179-2.675	0.006	1.357	0.913-2.018	0.131
CA-199 (≥ 22/< 22)	1.631	1.122-2.370	0.010	1.357	0.981-1.876	0.065
Tumor size (≥ 5/< 5)	1.171	0.853-1.608	0.328	1.359	1.016-1.818	0.039
Tumor number (multiple/single)	1.686	1.204-2.362	0.002	1.953	1.436-2.658	< 0.001
Tumor differentiation (moderate-poor/well)	5.326	1.318-21.519	0.019	4.498	1.434-14.110	0.010
Macrovascular invasion	1.076	0.753-1.538	0.688	1.014	0.756-1.453	0.776
Microvascular invasion	1.683	1.062-2.667	0.027	2.022	1.325-3.088	0.001
Node positive	2.696	1.928-3.769	< 0.001	1.955	1.424-2.684	< 0.001
Perineural invasion	1.174	0.832-1.656	0.360	1.443	0.976-2.134	0.066
TNM stage (III/I-II)	1.663	1.090-2.539	0.018	1.529	1.130-2.068	0.006
NLR (> 2.65/≤ 2.65)	1.609	1.171-2.212	0.003	1.482	1.111-1.978	0.007
PLR (> 110/≤ 110)	1.482	1.069-2.055	0.018	1.325	0.989-1.776	0.060
SII (> 450/≤ 450)	1.774	1.285-2.449	< 0.001	1.455	1.088-1.946	0.011

M: Male; F: Female; CA-199: Carbohydrate antigen-199; TNM: Tumor-node-metastasis; NLR: Neutrophil to lymphocyte ratio; PLR: Platelet to lymphocyte ratio; SII: Systemic immune-inflammation index; HR: Hazard ratio; CI: Confidence interval.